CO2021014034A2 - Método para preparar formulaciones de péptidos estables - Google Patents
Método para preparar formulaciones de péptidos establesInfo
- Publication number
- CO2021014034A2 CO2021014034A2 CONC2021/0014034A CO2021014034A CO2021014034A2 CO 2021014034 A2 CO2021014034 A2 CO 2021014034A2 CO 2021014034 A CO2021014034 A CO 2021014034A CO 2021014034 A2 CO2021014034 A2 CO 2021014034A2
- Authority
- CO
- Colombia
- Prior art keywords
- preparing stable
- peptide formulations
- stable peptide
- preparing
- powder formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000000843 powder Substances 0.000 abstract 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un método mejorado para preparar una formulación en polvo que contiene un péptido. La presente invención también proporciona un método mejorado para preparar una formulación en polvo que contiene glucagón o un análogo de glucagón, en donde dicha formulación en polvo es adecuada para administración nasal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839246P | 2019-04-26 | 2019-04-26 | |
| PCT/US2020/028988 WO2020219391A1 (en) | 2019-04-26 | 2020-04-20 | Method for preparing stable peptide formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021014034A2 true CO2021014034A2 (es) | 2021-10-29 |
Family
ID=70554273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0014034A CO2021014034A2 (es) | 2019-04-26 | 2021-10-20 | Método para preparar formulaciones de péptidos estables |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220192988A1 (es) |
| EP (1) | EP3958838A1 (es) |
| JP (2) | JP7245926B2 (es) |
| KR (1) | KR20210143253A (es) |
| CN (1) | CN113727700A (es) |
| AR (1) | AR118690A1 (es) |
| AU (1) | AU2020261941B2 (es) |
| BR (1) | BR112021018325A2 (es) |
| CA (1) | CA3134757A1 (es) |
| CL (1) | CL2021002690A1 (es) |
| CO (1) | CO2021014034A2 (es) |
| EA (1) | EA202192475A1 (es) |
| EC (1) | ECSP21079422A (es) |
| IL (1) | IL286426A (es) |
| MA (1) | MA55757A (es) |
| MX (1) | MX2021012852A (es) |
| PE (1) | PE20212368A1 (es) |
| SG (1) | SG11202110413YA (es) |
| TW (1) | TWI771669B (es) |
| WO (1) | WO2020219391A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116718762A (zh) * | 2023-06-09 | 2023-09-08 | 上海品峰医疗科技有限公司 | 一种多肽类样本稳定剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK49791D0 (da) * | 1991-03-20 | 1991-03-20 | Novo Nordisk As | Nasalt pulverpraeparat |
| WO2003066669A2 (en) * | 2002-02-04 | 2003-08-14 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
| US20060074025A1 (en) * | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
| PL2370462T3 (pl) | 2008-12-15 | 2015-01-30 | Zealand Pharma As | Analogi glukagonu |
| US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
| CN102292347A (zh) | 2008-12-15 | 2011-12-21 | 西兰制药公司 | 胰高血糖素类似物 |
| SI2454282T1 (sl) | 2009-07-13 | 2015-06-30 | Zealand Pharma A/S | Acilirani glukagonski analogi |
| JP2013523620A (ja) | 2010-03-26 | 2013-06-17 | ノヴォ ノルディスク アー／エス | 新規のグルカゴンアナログ |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| KR20130086343A (ko) | 2010-06-24 | 2013-08-01 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| CA2839867A1 (en) | 2011-06-22 | 2012-12-27 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US20130316941A1 (en) | 2011-12-23 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Glucagon analogues |
| FI124134B (en) | 2012-07-02 | 2014-03-31 | One Way Sport Oy | Binding between a ski and a ski boot |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9018162B2 (en) * | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| CR20170373A (es) * | 2015-02-17 | 2017-09-18 | Lilly Co Eli | Formulación en polvo nasal para el tratamiento de hipogligemia |
-
2020
- 2020-04-14 TW TW109112446A patent/TWI771669B/zh active
- 2020-04-15 AR ARP200101057A patent/AR118690A1/es unknown
- 2020-04-20 EP EP20724361.9A patent/EP3958838A1/en active Pending
- 2020-04-20 CN CN202080027937.1A patent/CN113727700A/zh active Pending
- 2020-04-20 AU AU2020261941A patent/AU2020261941B2/en active Active
- 2020-04-20 JP JP2021560275A patent/JP7245926B2/ja active Active
- 2020-04-20 SG SG11202110413YA patent/SG11202110413YA/en unknown
- 2020-04-20 EA EA202192475A patent/EA202192475A1/ru unknown
- 2020-04-20 PE PE2021001736A patent/PE20212368A1/es unknown
- 2020-04-20 US US17/606,214 patent/US20220192988A1/en active Pending
- 2020-04-20 KR KR1020217034137A patent/KR20210143253A/ko not_active Application Discontinuation
- 2020-04-20 WO PCT/US2020/028988 patent/WO2020219391A1/en unknown
- 2020-04-20 CA CA3134757A patent/CA3134757A1/en active Pending
- 2020-04-20 MA MA055757A patent/MA55757A/fr unknown
- 2020-04-20 MX MX2021012852A patent/MX2021012852A/es unknown
- 2020-04-20 BR BR112021018325A patent/BR112021018325A2/pt unknown
-
2021
- 2021-09-14 IL IL286426A patent/IL286426A/en unknown
- 2021-10-14 CL CL2021002690A patent/CL2021002690A1/es unknown
- 2021-10-20 CO CONC2021/0014034A patent/CO2021014034A2/es unknown
- 2021-10-26 EC ECSENADI202179422A patent/ECSP21079422A/es unknown
-
2023
- 2023-03-13 JP JP2023038306A patent/JP2023075249A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023075249A (ja) | 2023-05-30 |
| ECSP21079422A (es) | 2021-11-30 |
| EA202192475A1 (ru) | 2022-01-28 |
| PE20212368A1 (es) | 2021-12-21 |
| US20220192988A1 (en) | 2022-06-23 |
| AU2020261941B2 (en) | 2023-04-06 |
| AU2020261941A1 (en) | 2021-10-14 |
| KR20210143253A (ko) | 2021-11-26 |
| CL2021002690A1 (es) | 2022-07-08 |
| JP7245926B2 (ja) | 2023-03-24 |
| CA3134757A1 (en) | 2020-10-29 |
| MA55757A (fr) | 2022-03-02 |
| JP2022529614A (ja) | 2022-06-23 |
| TW202108599A (zh) | 2021-03-01 |
| MX2021012852A (es) | 2021-12-10 |
| TWI771669B (zh) | 2022-07-21 |
| SG11202110413YA (en) | 2021-10-28 |
| AR118690A1 (es) | 2021-10-27 |
| EP3958838A1 (en) | 2022-03-02 |
| BR112021018325A2 (pt) | 2021-11-23 |
| IL286426A (en) | 2021-10-31 |
| CN113727700A (zh) | 2021-11-30 |
| WO2020219391A1 (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116605A1 (es) | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) | |
| SV2017005515A (es) | Formulaciones de polvo nasal para el tratamiento de la hipoglicemia | |
| WO2019087083A3 (en) | Oral delivery of glp-1 peptide analogs | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| MX2021006969A (es) | Ligante peptidico. | |
| PH12018502615A1 (en) | Depot formulations | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| ECSP21060917A (es) | Formulación de anticuerpos terapéuticos | |
| ECSP21079422A (es) | Método para preparar formulaciones de péptidos estables | |
| CL2022001486A1 (es) | Formulaciones de anticuerpos anti-pd-l1. | |
| MX2020010085A (es) | Formulaciones que contienen péptidos. | |
| MX2020000144A (es) | Composicion farmaceutica para administracion nasal. | |
| CL2022001085A1 (es) | Formulación de anticuerpo que contiene crizanlizumab | |
| BR112018006969A2 (pt) | derivados de azetidina para formação de imagem de tau | |
| MX2020010928A (es) | Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea. | |
| EA202191327A1 (ru) | Лекарственные формы терапевтических препаратов от гриппа | |
| EA202092373A1 (ru) | Сухая порошкообразная фармацевтическая композиция для ингаляции, содержащая тиреоидный гормон | |
| BR112021026575A2 (pt) | Composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1 | |
| CY1123966T1 (el) | Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας |